Logo

American Heart Association

  17
  0


Final ID: Sun507

Artificial Intelligence Driven Subphenotyping of In-Hospital Cardiac Arrest Patients Identifies Subgroups with Different Outcomes and Risk Factors: A Nation-Wide Analysis

Abstract Body: Introduction: Disparities in outcomes after in-hospital cardiac arrest (IHCA) across race, ethnicity, and socioeconomic status are impacted by social determinants of health (SDOH) and health care access. We applied unsupervised machine learning methodologies to identify novel patient-level IHCA subphenotypes by integrating clinical and sociodemographic data, and safety-net hospital (SNH) status.

Methods: We utilized a cohort of 431,847 patients who suffered an IHCA from the American Heart Association Get with the Guidelines-Resuscitation Registry that included demographic characteristics, resuscitation outcomes and processes, and SDOH features. We implemented K-means clustering and hierarchical clustering with factor analysis for mixed data to identify subphenotypes. The primary outcome was survival to discharge and survival with good neurological status as defined by cerebral performance category (CPC) 1-2. We then compared survival outcomes across subphenotypes using Cox proportional hazards models.

Results: Subphenotype A (n = 307,668) consisted of patients with high burden of comorbidities and the highest rates of unmet social needs. This subphrnotype had the lowest survival to discharge (19.1%) and good neurological outcomes proportion (12.2%) as compared to other subphenotypes (Figure 1). Subphenotype B (n = 57,356) was composed of patients who experienced high rates of respiratory disease and primarily arrested in the emergency department. Subphenotype C (n = 66,823) were more likely to undergo intubation during resusciation and demonstrated the best survival to discharge proportion (43.6%) and good neurological outcomes (32.2%). Subphenotype assignment was independently associated with survival (HR 0.766, 95% CI 0.755–0.776) and good neurological outcomes (HR 0.770, 95% CI 0.757–0.783) (Figure 2). Subphenotype A patients were more likely to receive care at safety-net hospitals (20.1%) compared to subphenotype C (17.1%). Treatment at a SNH was an independent predictor of lower survival (AUROC 0.82) and poorer neurological recovery (AUROC 0.80) (Figure 3).

Conclusion: Using a large IHCA registry we identified three IHCA subphenotypes with significant differences in survival and neurological outcomes. By combining hospital structural features with detailed clinical and resuscitation data, this study offers a better understanding of IHCA risk across institutions and populations to inform targeted interventions.
  • Jiang, Joy  ( Icahn School of Medicine at Mount Sinai , New York , New York , United States )
  • Zebrowski, Alexis  ( Icahn School of Med at Mount Sinai , New York , New York , United States )
  • Bhatt, Deepak  ( Icahn School of Med at Mount Sinai , New York , New York , United States )
  • Nadkarni, Girish  ( ICAHN SCHOOL OF MEDICINE AT MOUNT S , New York , New York , United States )
  • Abbott, Ethan  ( Icahn School of Medicine at Mount Sinai , New York , New York , United States )
  • Oh, Wonsuk  ( Icahn School of Medicine at Mount S , New York , New York , United States )
  • Buckler, David  ( Icahn School of Med at Mount Sinai , New York , New York , United States )
  • Kittrell, Hannah  ( Icahn School of Med at Mount Sinai , New York , New York , United States )
  • Jayaraman, Pushkala  ( Icahn School of Med at Mount Sinai , New York , New York , United States )
  • Chan, Lili  ( Icahn School of Medicine at Mount S , New York , New York , United States )
  • Vaid, Akhil  ( Icahn Sch. of Medicine at Mt. Sinai , New York City , New York , United States )
  • Gulamali, Faris  ( Icahn Sch. of Medicine at Mt. Sinai , New York City , New York , United States )
  • Redlener, Michael  ( Icahn School of Med at Mount Sinai , New York , New York , United States )
  • Author Disclosures:
    Joy Jiang: No Answer | alexis zebrowski: No Answer | Deepak Bhatt: DO have relevant financial relationships ; Advisor:Angiowave, Antlia Bioscience, Bayer, Boehringer Ingelheim, CellProthera, Cereno Scientific, E-Star Biotech, High Enroll, Janssen, Level Ex, McKinsey, Medscape Cardiology, Merck, NirvaMed, Novo Nordisk, Repair Biotechnologies, Stasys, Tourmaline Bio:Active (exists now) ; Other (please indicate in the box next to the company name):Site Co-Investigator: Cleerly.:Active (exists now) ; Royalties/Patent Beneficiary:Patent: Sotagliflozin (named on a patent for sotagliflozin assigned to Brigham and Women's Hospital who assigned to Lexicon; neither I nor Brigham and Women's Hospital receive any income from this patent);:Active (exists now) ; Royalties/Patent Beneficiary:Royalties: Elsevier (Editor, Braunwald’s Heart Disease);:Active (exists now) ; Researcher:Abbott, Acesion Pharma, Afimmune, Alnylam, Amarin, Amgen, AstraZeneca, Atricure, Bayer, Boehringer Ingelheim, Boston Scientific, CellProthera, Cereno Scientific, Chiesi, Cleerly, CSL Behring, Faraday Pharmaceuticals, Fractyl, Idorsia, Janssen, Javelin, Lexicon, Lilly, Medtronic, Merck, MiRUS, Moderna, Novartis, Novo Nordisk, Pfizer, PhaseBio, Regeneron, Reid Hoffman Foundation, Roche, Sanofi, Stasys, 89Bio;:Active (exists now) ; Other (please indicate in the box next to the company name):Other: Clinical Cardiology (Deputy Editor); Progress in Cardiovascular Diseases (Deputy Editor):Active (exists now) ; Other (please indicate in the box next to the company name):Honoraria: American College of Cardiology (Senior Associate Editor, Clinical Trials and News, ACC.org; Chair, ACC Accreditation Oversight Committee), Arnold and Porter law firm (work related to Sanofi/Bristol-Myers Squibb clopidogrel litigation), Baim Institute for Clinical Research (AEGIS-II executive committee funded by CSL Behring), Belvoir Publications (Editor in Chief, Harvard Heart Letter), Canadian Medical and Surgical Knowledge Translation Research Group (clinical trial steering committees), CSL Behring (AHA lecture), Duke Clinical Research Institute, Engage Health Media, HMP Global (Editor in Chief, Journal of Invasive Cardiology), Medtelligence/ReachMD (CME steering committees), MJH Life Sciences, Oakstone CME (Course Director, Comprehensive Review of Interventional Cardiology), Philips (Becker's Webinar on AI), Population Health Research Institute, WebMD (CME steering committees), Wiley (steering committee);:Active (exists now) ; Individual Stocks/Stock Options:Angiowave (stock options), Bristol Myers Squibb (stock), DRS.LINQ (stock options), High Enroll (stock):Active (exists now) ; Other (please indicate in the box next to the company name):Data Monitoring Committees: Acesion Pharma, Assistance Publique-Hôpitaux de Paris, Baim Institute for Clinical Research, Boston Scientific (Chair, PEITHO trial), Cleveland Clinic, Contego Medical (Chair, PERFORMANCE 2), Duke Clinical Research Institute, Mayo Clinic, Mount Sinai School of Medicine (for the ABILITY-DM trial, funded by Concept Medical; for ALLAY-HF, funded by Alleviant Medical), Novartis, Population Health Research Institute; Rutgers University (for the NIH-funded MINT Trial);:Active (exists now) ; Consultant:Alnylam, Altimmune, Broadview Ventures, Corcept Therapeutics, Corsera, GlaxoSmithKline, Hims, SERB, SFJ, Summa Therapeutics:Active (exists now) ; Other (please indicate in the box next to the company name):Board of Directors: American Heart Association New York City, Angiowave (stock options), Bristol Myers Squibb (stock), DRS.LINQ (stock options), High Enroll (stock);:Active (exists now) | Girish Nadkarni: No Answer | Ethan Abbott: DO NOT have relevant financial relationships | Wonsuk Oh: DO NOT have relevant financial relationships | David Buckler: DO NOT have relevant financial relationships | Hannah Kittrell: No Answer | Pushkala Jayaraman: No Answer | Lili Chan: DO have relevant financial relationships ; Consultant:Vifor Pharma:Active (exists now) | Akhil Vaid: No Answer | Faris Gulamali: No Answer | Michael Redlener: DO NOT have relevant financial relationships
Meeting Info:

Resuscitation Science Symposium 2025

2025

New Orleans, Louisiana

Session Info:

Epidemiology III

Sunday, 11/09/2025 , 01:30PM - 03:00PM

ReSS25 Poster Session and Reception

More abstracts on this topic:
A Case of Successful Resuscitation After Out-of-hospital Cardiac Arrest Caused by Undiagnosed Pheochromocytoma-induced Cardiomyopathy

Hatakeyama Toshihiro, Suetsugu Yusuke, Watanabe Kaoru, Matsushima Hisao

An Assessment of the Baseline Characteristics of Participants in the Pilot THRIVE Food is Medicine Study

Washington India, Demarco Samantha, Tomiwa Tosin, Olusola-bello Mojisola, Kyeremeh Djanee, Mcmahon Adrian, Kramer Maya, Saldarriaga Maricielo, Chen Peiyu, Rodriguez Christy, Johnson Mia, Song Shanshan, Xiao William, Gledhill Samuel, Yeboah-manson Samuel, Kurien Natania, Vassiliadi Lydia, Freeman Jennifer, Izquierdo-porrera Anna Maria, Palencia Lessly, Sullivan Valerie, Commodore-mensah Yvonne, Alvarez Kiara, Ogungbe Bunmi, Akubo Chelsea, Adeleye Khadijat, Iribe Irma, Assani-uva Adeline, Dugbartey Janice, Sinyan Aminata

More abstracts from these authors:
The impact of safety net hospital status on survival among in-hospital cardiac arrest patients in a US registry

Buckler David, Jiang Joy, Oh Wonsuk, Shekhar Aditya, Redlener Michael, Zebrowski Alexis, Abella Benjamin, Nadkarni Girish, Abbott Ethan

Diagnosis of Left Ventricular Diastolic Dysfunction using Deep Learning on electrocardiograms

Shetty Samantha, Lampert Joshua, Jiang Joy, Nadkarni Girish, Vaid Akhil

You have to be authorized to contact abstract author. Please, Login
Not Available